Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 20/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13205336 | 0.93 | CXCR3 (0.81) | CXCR3 | |
| SCHEMBL13205868 | 0.93 | CXCR3 (1.00) | CXCR3 | |
| SCHEMBL13205308 | 0.92 | CXCR3 (0.78) | CXCR3 | |
| SCHEMBL13205408 | 0.92 | CXCR3 (0.84) | CXCR3 | |
| SCHEMBL13205291 | 0.92 | CXCR3 (0.87) | CXCR3 | |
| SCHEMBL13205422 | 0.91 | CXCR3 (0.86) | CXCR3 | |
| SCHEMBL13205462 | 0.91 | CXCR3 (0.86) | CXCR3 | |
| SCHEMBL13224719 | 0.90 | CXCR3 (0.74) | CXCR3 | |
| SCHEMBL13205413 | 0.90 | CXCR3 (0.74) | CXCR3 | |
| SCHEMBL13205864 | 0.90 | CXCR3 (0.84) | CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776862-B2 | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776862-B2 | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| US-20070021611-A1 | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20070021611-A1 | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021611-A1 | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | CXCR3, CCR1, CCR5 | CXCR3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.